Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis

被引:7
作者
Ao, Guangyu [1 ]
Li, Toni [2 ]
Wang, Yushu [3 ]
Tran, Carolyn [4 ]
Qi, Xin [5 ,6 ]
机构
[1] Chengdu First Peoples Hosp, Dept Nephrol, Chengdu, Sichuan, Peoples R China
[2] Queens Univ, Sch Med, Kingston, ON, Canada
[3] Chengdu West China Clin Res Ctr, Chengdu, Sichuan, Peoples R China
[4] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[5] Southwest Jiaotong Univ, Affiliated Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China
[6] Third Peoples Hosp Chengdu, Chengdu, Sichuan, Peoples R China
关键词
D O I
10.1016/j.jinf.2022.04.027
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
引用
收藏
页码:E10 / E12
页数:3
相关论文
共 11 条
[1]  
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, 2021, Lancet Infect Dis.
[2]  
Bergquist Sharon H, 2020, SN Compr Clin Med, V2, P1349, DOI [10.1145/3384441.3395981, 10.1007/s42399-020-00453-3]
[3]   Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial [J].
Gupta, Anil ;
Gonzalez-Rojas, Yaneicy ;
Juarez, Erick ;
Casal, Manuel Crespo ;
Moya, Jaynier ;
Falci, Diego Rodrigues ;
Sarkis, Elias ;
Solis, Joel ;
Zheng, Hanzhe ;
Scott, Nicola ;
Cathcart, Andrea L. ;
Parra, Sergio ;
Sager, Jennifer E. ;
Austin, Daren ;
Peppercorn, Amanda ;
Alexander, Elizabeth ;
Yeh, Wendy W. ;
Brinson, Cynthia ;
Aldinger, Melissa ;
Shapiro, Adrienne E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (13) :1236-1246
[4]   Sotrovimab: First Approval [J].
Heo, Young-A .
DRUGS, 2022, 82 (04) :477-484
[5]   The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic [J].
Hoffmann, Markus ;
Krueger, Nadine ;
Schulz, Sebastian ;
Cossmann, Anne ;
Rocha, Cheila ;
Kempf, Amy ;
Nehlmeier, Inga ;
Graichen, Luise ;
Moldenhauer, Anna-Sophie ;
Winkler, Martin S. ;
Lier, Martin ;
Dopfer-Jablonka, Alexandra ;
Jaeck, Hans-Martin ;
Behrens, Georg M. N. ;
Poehlmann, Stefan .
CELL, 2022, 185 (03) :447-+
[6]   Nature does things well [J].
不详 .
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2022, (184) :288-288
[7]  
Huang D.T., 2021, EFFECTIVENESS CASIRI, DOI [10.1101/2021.12.23.21268244, DOI 10.1101/2021.12.23.21268244]
[8]  
Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4
[9]   Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis [J].
Luo, Lili ;
Luo, Ting ;
Du, Mengyi ;
Mei, Heng ;
Hu, Yu .
JOURNAL OF INFECTION, 2022, 84 (03) :433-438
[10]   Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study [J].
Ong, Sean W. X. ;
Ren, Dongdong ;
Lee, Pei Hua ;
Sutjipto, Stephanie ;
Dugan, Christopher ;
Khoo, Bo Yan ;
Tay, Jun Xin ;
Vasoo, Shawn ;
Young, Barnaby E. ;
Lye, David C. .
ANTIBIOTICS-BASEL, 2022, 11 (03)